764 Shares in Eli Lilly and Company (NYSE:LLY) Acquired by Atlas Legacy Advisors LLC

Atlas Legacy Advisors LLC purchased a new stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 764 shares of the company's stock, valued at approximately $590,000.

Several other hedge funds and other institutional investors also recently modified their holdings of the company. AMF Tjanstepension AB raised its stake in shares of Eli Lilly and Company by 113.7% during the third quarter. AMF Tjanstepension AB now owns 331,786 shares of the company's stock valued at $293,964,000 after purchasing an additional 176,552 shares in the last quarter. Values Added Financial LLC raised its stake in shares of Eli Lilly and Company by 4.9% during the third quarter. Values Added Financial LLC now owns 366 shares of the company's stock valued at $324,000 after purchasing an additional 17 shares in the last quarter. Kessler Investment Group LLC raised its stake in shares of Eli Lilly and Company by 129.7% during the third quarter. Kessler Investment Group LLC now owns 5,687 shares of the company's stock valued at $5,038,000 after purchasing an additional 3,211 shares in the last quarter. RFP Financial Group LLC raised its stake in shares of Eli Lilly and Company by 89.4% during the third quarter. RFP Financial Group LLC now owns 2,580 shares of the company's stock valued at $2,285,000 after purchasing an additional 1,218 shares in the last quarter. Finally, Graybill Wealth Management LTD. raised its stake in shares of Eli Lilly and Company by 5.3% during the third quarter. Graybill Wealth Management LTD. now owns 895 shares of the company's stock valued at $793,000 after purchasing an additional 45 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the stock. Citigroup cut their price objective on shares of Eli Lilly and Company from $1,250.00 to $1,190.00 and set a "buy" rating on the stock in a research note on Tuesday, January 28th. StockNews.com upgraded shares of Eli Lilly and Company from a "hold" rating to a "buy" rating in a research note on Friday, February 7th. Barclays dropped their price target on shares of Eli Lilly and Company from $1,025.00 to $975.00 and set an "overweight" rating on the stock in a research report on Thursday, October 31st. Deutsche Bank Aktiengesellschaft dropped their price target on shares of Eli Lilly and Company from $1,025.00 to $1,015.00 and set a "buy" rating on the stock in a research report on Monday, November 4th. Finally, Wells Fargo & Company dropped their price target on shares of Eli Lilly and Company from $1,000.00 to $970.00 and set an "overweight" rating on the stock in a research report on Tuesday, January 28th. Four investment analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company's stock. According to MarketBeat, Eli Lilly and Company has a consensus rating of "Moderate Buy" and a consensus price target of $997.50.

Eli Lilly and Company Trading Up 0.4 %

LLY traded up $3.50 during trading on Friday, reaching $876.62. The company had a trading volume of 2,775,916 shares, compared to its average volume of 3,728,728. The company has a debt-to-equity ratio of 2.03, a quick ratio of 0.97 and a current ratio of 1.27. Eli Lilly and Company has a 12-month low of $711.40 and a 12-month high of $972.53. The firm's 50-day simple moving average is $799.63 and its 200 day simple moving average is $846.07. The company has a market cap of $832.19 billion, a price-to-earnings ratio of 74.82, a PEG ratio of 1.39 and a beta of 0.42.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its earnings results on Thursday, February 6th. The company reported $5.32 earnings per share for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 86.26%. Equities research analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, March 10th. Shareholders of record on Friday, February 14th will be paid a dividend of $1.50 per share. This represents a $6.00 annualized dividend and a yield of 0.68%. The ex-dividend date is Friday, February 14th. This is a boost from Eli Lilly and Company's previous quarterly dividend of $1.30. Eli Lilly and Company's payout ratio is 51.24%.

Eli Lilly and Company announced that its Board of Directors has approved a stock buyback plan on Monday, December 9th that permits the company to repurchase $15.00 billion in shares. This repurchase authorization permits the company to buy up to 2% of its shares through open market purchases. Shares repurchase plans are generally an indication that the company's board believes its stock is undervalued.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.